TABLE 3

SVR12 rates in the presence and absence of baseline polymorphisms in NS3 or NS5A in GT1a-infected patients

Target and polymorphismaSVR12 rate (%) by patient population, prior treatment experience, and treatment durationb
No cirrhosisCompensated cirrhosis
TN (8 wk)TE-PRS (8 wk)TN (12 wk)TE-PRS (12 wk)TN (12 wk)TE-PRS (12 wk)
NS3
    Polymorphism at aa 155, 156, or 168100 (5/5)100 (1/1)100 (1/1)100 (1/1)
    No polymorphisms100 (129/129)97.3 (36/37)100 (112/112)100 (47/47)100 (39/39)91.7 (11/12)
    With Q80K100 (48/48)100 (12/12)100 (40/40)100 (9/9)100 (21/21)100 (5/5)
    Without Q80K100 (86/86)96.0 (24/25)100 (73/73)100 (39/39)100 (19/19)85.7 (6/7)
NS5A
    Polymorphism at aa 24, 28, 30, 31, 58, 92, or 93100 (27/27)100 (9/9)100 (24/24)100 (6/6)100 (10/10)50.0 (1/2)c
    No polymorphisms100 (105/105)96.6 (28/29)100 (86/86)100 (41/41)100 (29/29)100 (12/12)
  • a Polymorphisms relative to subtype-specific reference sequence at a 15% detection threshold. aa, amino acid.

  • b Values in parentheses are the number of patients who achieved SVR12/total number of patients in the group with available sequence. TE-PRS, treatment-experienced to peg-IFN plus RBV with or without sofosbuvir; TN, treatment-naive.

  • c Patient experiencing virologic failure had a Y93N substitution in NS5A at baseline.